These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 24032379)
1. Faster, higher, stronger. Rubin BK Am J Respir Crit Care Med; 2013 Sep; 188(6):634-5. PubMed ID: 24032379 [No Abstract] [Full Text] [Related]
2. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum. Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381 [TBL] [Abstract][Full Text] [Related]
3. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum. Sun F; Tai S; Lim T; Baumann U; King M Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485 [TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients. Hansen G; Hoffjan S; Mosler K; Schuster A Lung; 2001; 179(3):185-94. PubMed ID: 11891608 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. Wilms EB; Touw DJ; Heijerman HG J Cyst Fibros; 2008 Jan; 7(1):79-84. PubMed ID: 17599845 [TBL] [Abstract][Full Text] [Related]
6. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Shibuya Y; Wills PJ; Cole PJ Respiration; 2001; 68(6):615-9. PubMed ID: 11786718 [TBL] [Abstract][Full Text] [Related]
7. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. Lieberman J JAMA; 1968 Jul; 205(5):312-3. PubMed ID: 5694947 [No Abstract] [Full Text] [Related]
8. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Cunningham S; McColm JR; Mallinson A; Boyd I; Marshall TG Pediatr Pulmonol; 2003 Jul; 36(1):43-8. PubMed ID: 12772222 [TBL] [Abstract][Full Text] [Related]
9. Effect of tolazoline hydrochloride on sputum viscosity in cystic fibrosis. Feather EA; Russell G Thorax; 1970 Nov; 25(6):732-6. PubMed ID: 5494682 [TBL] [Abstract][Full Text] [Related]
10. Proteolytic enzyme activity and the role of desoxyribose nucleic acid (DNA) in cystic fibrosis sputum. LIEBERMAN J; KURNICK NB Pediatrics; 1963 Jun; 31():1028-32. PubMed ID: 13930542 [No Abstract] [Full Text] [Related]
11. [Pharmaccokinetics of various antibiotics on mucoviscidosis with special reference to their concentration in sputum in relation to its chemical composition]. Bonomi U; Marcer V; Piacentini I; Bravi A; Battaglino G; Stizzoli R; Mastella G Fracastoro; 1970; 63(3):579-609. PubMed ID: 5517030 [No Abstract] [Full Text] [Related]
12. Trace incorporation of heavy water reveals slow and heterogeneous pathogen growth rates in cystic fibrosis sputum. Kopf SH; Sessions AL; Cowley ES; Reyes C; Van Sambeek L; Hu Y; Orphan VJ; Kato R; Newman DK Proc Natl Acad Sci U S A; 2016 Jan; 113(2):E110-6. PubMed ID: 26715741 [TBL] [Abstract][Full Text] [Related]
13. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269 [TBL] [Abstract][Full Text] [Related]
14. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802 [TBL] [Abstract][Full Text] [Related]
15. Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum. Devereux G; Fraser-Pitt D; Robertson J; Devlin E; Mercer D; O'Neil D EBioMedicine; 2015 Oct; 2(10):1507-12. PubMed ID: 26629546 [TBL] [Abstract][Full Text] [Related]
16. Acetylcysteine in the oral mucolytic treatment of cystic fibrosis. Stephan U; Böwing B; Goering U; Wiesemann HG; Reinhardt M; Hirche H; Brandt H Eur J Respir Dis Suppl; 1980; 111():127-31. PubMed ID: 6938396 [No Abstract] [Full Text] [Related]
17. The effect of augmentin on sputum beta-lactamase activity in patients with cystic fibrosis. Penketh AR; Hodson ME; Batten JC Br J Clin Pract; 1984 May; 38(5):188-9. PubMed ID: 6610437 [No Abstract] [Full Text] [Related]
18. Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate. Stigliani M; Manniello MD; Zegarra-Moran O; Galietta L; Minicucci L; Casciaro R; Garofalo E; Incarnato L; Aquino RP; Del Gaudio P; Russo P J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):337-45. PubMed ID: 26741302 [TBL] [Abstract][Full Text] [Related]
19. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Sanders NN; Franckx H; De Boeck K; Haustraete J; De Smedt SC; Demeester J Thorax; 2006 Nov; 61(11):962-8. PubMed ID: 17071834 [TBL] [Abstract][Full Text] [Related]